NEW YORK (GenomeWeb) – Progenity said today that it has acquired proteomic diagnostic company Carmenta Bioscience.

A spin-out of Stanford University, Carmenta is focused on developing a protein-based test for preeclampsia, a hypertensive disorder of pregnancy. Preeclampsia is a leading cause of preterm births and maternal fetal deaths, with between 5 and 8 percent of pregnant women developing the condition.

Under the terms of the acquisition, Carmenta CEO Matthew Cooper will join Progenity as chief scientific officer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.